HHS Price Negotiations For Part D Not A Problem For Medco, CEO Snow Says
Medco is not worried about the possibility that the federal government may step in to negotiate drug prices for the Medicare Part D program, according to CEO David Snow
You may also be interested in...
Medco is promoting a health care reform agenda that emphasizes cost savings from more efficient and effective care instead of focusing on who pays the bills
Sen. Baucus’ effort to simply strike the non-interference clause, rather than requiring negotiations, did not garner enough support to force a vote.
Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.